Blood Fibrin(ogen) Amyloid Fluorescence Detection for Early Inflammation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting amyloid levels in inflammation are poorly sensitive, expensive, and time-consuming, limiting their application in under-resourced clinical contexts, and fail to detect low levels of amyloid formation at early stages of disease progression.
Innovation Solution
A method involving the use of amyloid-binding fluorescent markers to detect fibrin(ogen) amyloid in blood samples, measuring fluorescence to quantify amyloid levels, and correlating these levels with inflammation through reference values or charts, enabling early detection of inflammation and disease states.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If enzyme-linked immunosorbent assays (ELISA) and mass spectrometry (MS) are used to detect SAA levels, then detection accuracy is achieved, but cost and time consumption increase significantly
Solution Approach 1:
The patent replaces complex mechanical/chemical assay systems (ELISA, MS) with a fluorescent detection system that uses fluorescent markers to bind to amyloid-SAA complexes. This optical detection method significantly reduces detection time while maintaining sensitivity, as fluorescent signals can be measured rapidly without the lengthy incubation and processing steps required by ELISA or MS.
Solution Approach 2:
The patent utilizes fluorescent markers that emit light at specific wavelengths when bound to amyloid-SAA complexes. The fluorescent signal intensity correlates with SAA levels, enabling rapid quantitative detection. This optical approach allows for real-time or near-real-time measurement without the time-consuming steps of traditional assays.
2Measurement precision
If ELISA and MS methods are employed for SAA detection, then measurement precision is maintained, but cost increases to levels that limit application in under-resourced settings
Solution Approach 1:
The patent employs fluorescent markers that can be used in simple, disposable test formats. These fluorescent probes are chemically stable but economically inexpensive compared to the reagents and equipment required for ELISA or MS. The method enables low-cost detection that can be performed in resource-limited settings while maintaining adequate sensitivity for clinical diagnosis.
3Measurement precision
If conventional detection methods are used, then existing detection capability is maintained, but sensitivity remains insufficient for early disease detection
Solution Approach 1:
The patent introduces fluorescent markers as intermediary molecules that specifically bind to amyloid-SAA complexes. These markers amplify the detection signal and enable sensitive detection of low-level SAA production that occurs in early disease stages. The fluorescent intermediaries convert subtle biochemical changes into easily measurable optical signals, enhancing sensitivity without requiring complex instrumentation.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Provides a convenient, non-invasive, and sensitive method for detecting early-stage inflammation, allowing for accurate monitoring of disease progression and therapeutic response, reducing costs and time compared to existing methods.
Implementation Method 1
contacting the blood sample with an amyloid-binding fluorescent marker, allowing amyloid in the sample to bind to the marker, measuring fluorescence emitted upon binding of the amyloid to the marker
Data Source
AI summary
A method of detecting inflammation in a subject is provided. The method comprises determining a quantity of amyloid present in fibrin(ogen) protein in a blood sample obtained from the subject, and assigning a level of inflammation in the subject based on the quantity of fibrin(ogen) amyloid determined. A method of determining an effect of a therapeutic treatment on a subject by comparing a pre-treatment level of inflammation with a post-treatment level is further provided.